Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein (Q31120123)

29 June 2017

1 reference

title

Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein (English)

1 reference

29 June 2017

0 references

0 references

0 references

1 reference

2

Patrik Brundin

1 reference

29 June 2017

Julie Lotharius

1

1 reference

29 June 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Nature Reviews Neuroscience

29 June 2017

published in

1 reference

29 June 2017

volume

3

1 reference

29 June 2017

issue

12

1 reference

29 June 2017

page(s)

932-942

1 reference

Parkinson's disease: one biochemical pathway to fit all genes?

29 June 2017

cites work

1 reference

Genetics of Parkinson's disease and biochemical studies of implicated gene products

31 March 2020

1 reference

Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases

31 March 2020

1 reference

Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.

31 March 2020

1 reference

Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat

31 March 2020

1 reference

Oxidative stress, caloric restriction, and aging

31 March 2020

1 reference

Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease

31 March 2020

1 reference

Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain.

31 March 2020

1 reference

Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease

31 March 2020

1 reference

Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease

31 March 2020

1 reference

Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease

31 March 2020

1 reference

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

31 March 2020

1 reference

Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients

31 March 2020

1 reference

Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates

31 March 2020

1 reference

Reactive oxygen species and the central nervous system

31 March 2020

1 reference

Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain

31 March 2020

1 reference

A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra

31 March 2020

1 reference

Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease

31 March 2020

1 reference

Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay.

31 March 2020

1 reference

Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra.

31 March 2020

1 reference

Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease

31 March 2020

1 reference

Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease

31 March 2020

1 reference

Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons

31 March 2020

1 reference

A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease.

31 March 2020

1 reference

Glutathione, oxidative stress and neurodegeneration

31 March 2020

1 reference

Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus

31 March 2020

1 reference

Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease

31 March 2020

1 reference

Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains

31 March 2020

1 reference

Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis

31 March 2020

1 reference

Nigral dopaminergic cell loss in vitamin E deficient rats

31 March 2020

1 reference

High-affinity binding of [3H]1-methyl-4-phenyl-2,3-dihydropyridinium ion to mouse striatal membranes: putative vesicular location

31 March 2020

1 reference

Characterization of a putatively vesicular binding site for [3H]MPP+ in mouse striatal membranes

31 March 2020

1 reference

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine

31 March 2020

1 reference

Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+

31 March 2020

1 reference

Interaction of 1-methyl-4-phenylpyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase.

31 March 2020

1 reference

A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

31 March 2020

1 reference

Evidence that the blockade of mitochondrial respiration by the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) involves binding at the same site as the respiratory inhibitor, rotenone

31 March 2020

1 reference

The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity

31 March 2020

1 reference

Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter

31 March 2020

1 reference

Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action.

31 March 2020

1 reference

Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport

31 March 2020

1 reference

Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections

31 March 2020

1 reference

Treatment of mice with methamphetamine produces cell loss in the substantia nigra

31 March 2020

1 reference

Methamphetamine-induced neuronal damage: a possible role for free radicals

31 March 2020

1 reference

CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA).

31 March 2020

1 reference

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

31 March 2020

1 reference

Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat

31 March 2020

1 reference

Pesticides and Parkinson's disease.

31 March 2020

1 reference

Environmental risk factors and Parkinson's disease: a case-control study in Taiwan

31 March 2020

1 reference

Mechanism of cytotoxicity of paraquat. I. NADH oxidation and paraquat radical formation via complex I.

31 March 2020

1 reference

Alpha-synuclein and neurodegenerative diseases

31 March 2020

1 reference

Alpha-synuclein in Lewy bodies

31 March 2020

1 reference

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

31 March 2020

1 reference

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease

31 March 2020

1 reference

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

31 March 2020

1 reference

Parkin and the molecular pathways of Parkinson's disease

31 March 2020

1 reference

The ubiquitin pathway in Parkinson's disease

31 March 2020

1 reference

The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility

31 March 2020

1 reference

Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study

31 March 2020

1 reference

Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly.

31 March 2020

1 reference

Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease

31 March 2020

1 reference

Monoclonal antibodies to purified cortical Lewy bodies recognize the mid-size neurofilament subunit

31 March 2020

1 reference

Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid

31 March 2020

1 reference

Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy

31 March 2020

1 reference

Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases

31 March 2020

1 reference

Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?

31 March 2020

1 reference

Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells

31 March 2020

1 reference

Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion

31 March 2020

1 reference

Contribution of somal Lewy bodies to neuronal death

31 March 2020

1 reference

Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease

31 March 2020

1 reference

Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.

31 March 2020

1 reference

Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?

31 March 2020

1 reference

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

31 March 2020

1 reference

Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease

31 March 2020

1 reference

Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.

31 March 2020

1 reference

Neurodegenerative disease: amyloid pores from pathogenic mutations

31 March 2020

1 reference

Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils

31 March 2020

1 reference

Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro

31 March 2020

1 reference

Aggregation of alpha-synuclein induced by the Cu,Zn-superoxide dismutase and hydrogen peroxide system

31 March 2020

1 reference

Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1

31 March 2020

1 reference

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase

31 March 2020

1 reference

Functional association of the parkin gene promoter with idiopathic Parkinson's disease

31 March 2020

1 reference

Lewy bodies and parkinsonism in families with parkin mutations

31 March 2020

1 reference

Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease

31 March 2020

1 reference

Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions

31 March 2020

1 reference

Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein

31 March 2020

1 reference

Impairment of the ubiquitin-proteasome system by protein aggregation

31 March 2020

1 reference

Proteasomal function is impaired in substantia nigra in Parkinson's disease

31 March 2020

1 reference

Brain proteasomal function in sporadic Parkinson's disease and related disorders

31 March 2020

1 reference

Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease

31 March 2020

1 reference

Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells

31 March 2020

1 reference

Proteasome inhibition causes nigral degeneration with inclusion bodies in rats

31 March 2020

1 reference

Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures

31 March 2020

1 reference

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system

31 March 2020

1 reference

Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein

31 March 2020

1 reference

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

31 March 2020

1 reference

Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line

31 March 2020

1 reference

Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity

31 March 2020

1 reference

Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene

31 March 2020

1 reference

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

31 March 2020

1 reference

Neuropathology in mice expressing human alpha-synuclein

31 March 2020

1 reference

Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein

31 March 2020

1 reference

Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice

31 March 2020

1 reference

A Drosophila model of Parkinson's disease

31 March 2020

1 reference

Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways.

31 March 2020

1 reference

Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture

31 March 2020

1 reference

Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease

31 March 2020

1 reference

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

31 March 2020

1 reference

Wild-type but not Parkinson's disease-related ala-53 --> Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli

31 March 2020

1 reference

alpha-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells

31 March 2020

1 reference

Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes

31 March 2020

1 reference

Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.

31 March 2020

1 reference

Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein

31 March 2020

1 reference

alpha-Synuclein membrane interactions and lipid specificity

31 March 2020

1 reference

Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins

31 March 2020

1 reference

alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells

31 March 2020

1 reference

Signalling roles of mammalian phospholipase D1 and D2.

31 March 2020

1 reference

Phospholipase D: molecular and cell biology of a novel gene family

31 March 2020

1 reference

Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease

31 March 2020

1 reference

Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons

31 March 2020

1 reference

Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain

31 March 2020

1 reference

Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice

31 March 2020

1 reference

Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter

31 March 2020

1 reference

Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice

31 March 2020

1 reference

Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRN983

1 reference

Dimensions Publication ID

29 June 2017

1026093879

0 references

1 reference